Unlock your Inner Self

The future of mental health and personal development is in psychedelic medicine. We are on a mission to develop a diverse portfolio of transformative medicinal products that enhance mental and physical health, addressing conditions such as PTSD, perinatal depression, anxiety, depression, addiction, TBI, obesity, and diabetes.

Our Vision

Industry Leading

Cube Psytech is a pioneering Vancouver-based biopharmaceutical and biotechnology company that is uniquely positioned to leverage growing trends in the psychedelic therapy industry. Our vision is to become the industry-leading bio-pharmaceutical and biotechnology company focused on psychedelics and alternative treatment options for patients around the world, ultimately generating significant value for our company investors and shareholders.

Industry Summary

The global biotechnology industry encompasses a vast array of global firms engaged in key research, development, and production activities for biotech-based products and services. The industry is characterized by its reliance on advanced scientific research and development – with firms ranging from small niche researchers to larger, diversified international conglomerates, with $477.1B in 2023 revenue. The industry has experienced stable growth rates, with 0.8% annualized growth (CAGR 2018-2023) via global pandemic-driven growth to the present day. A significant growth trend in the industry is the increasing focus on holistic, personalized medicine and biopharmaceuticals – driven by advancements in both R&D and subsequent shifts in government regulation and public perceptions which have enabled a favourable growth outlook. Over the next several years, the industry is anticipated to expand with 3.1% annualized growth (CAGR 2023-2028), driving up the industry average 19.3% profit margins worldwide.

Within global biotechnology and healthcare, the psychedelic medicine niche is emerging as a sector of interest – spurred by shifting perceptions and supported by modern clinical evidence of its efficacy in treating mental and physical conditions including (but not limited to) post-traumatic stress disorder (PTSD), perinatal depression (formerly postpartum depression), anxiety, substance abuse disorder, traumatic brain injury (TBI), obesity, and diabetes.

Psychedelic medicine and therapeutics have experienced rapid growth – particularly in North American markets, which comprise the largest share of global revenue – with an estimated $4.53B in 2023 revenue worldwide. The sector is forecast to grow at a 14.92% annualized growth rate (CAGR 2023-2031), reaching $13.29B by 2031 – equivalent to almost 200% market growth in under a decade. This rapid growth is further supported by shifts in North American and global demand levels for psychedelics (e.g., psilocybin-based products) and correspondingly benefits from a supportive regulatory environment – relative to even a decade ago – increasing acceptance and substantial investment in clinical trials.

While there are still regulatory hurdles and competition from the conventional pharmaceutical establishment, we believe opportunities are abundant – including the development of new therapeutic products, expansion into wellness facilities, and partnerships with R&D institutions – to capitalize on the growing demand for alternative mental health and wellness treatments that blend cutting-edge R&D with unconventional therapies.

Psychedelic therapies – as an option to conventional treatments – have been on the rise within biotechnology. While they vary between types, they typically involve a naturally occurring or synthesized psychedelic substance and are usually administered under the supervision of a qualified therapist. Patients undergoing psychedelic therapy typically experience altered states of consciousness which may include hallucinations, enhanced emotions, and intense introspection. An altered state allows patients to gain invaluable insights and apply them to their everyday lives, and significant research is also demonstrating the potential of psychedelic therapies to treat PTSD, perinatal depression, anxiety, depression, addiction, TBI, obesity, and diabetes – among other physiological conditions.

Current studies suggest that a few sessions of psychedelic therapy can be just as effective – or more so – than conventional therapies which often have key side effects.

The Future of Psychedelic Medicine

Cube Psytech’s key to success lies in our world-class R&D and science team, our proprietary technologies, and our experienced executive leadership, who leverage deep expertise in capital markets and start-ups. Building on this strong foundation, our company’s strategy focuses on creating innovative IP and proprietary tech via cutting-edge psychedelic R&D led by world-class scientists from within neurobiology, chemistry, botany, mycology, biology and mental health pharmacology fields.

Our corporate umbrella strategy includes specialized arms for the R&D of novel medicines, exclusive wellness retreat locations, production and procurement services, innovative product offerings, and comprehensive contract research capabilities – supported by a global network of key stakeholders and commitment to excellence.

Why is Cube Unique? Learn More

Investor Relations

best of class sciences and executive leadership team

Cube utilizes several interrelated corporate arms that specialize in R&D for our proprietary medicines, offer access to our exclusive wellness locations, provide production and procurement services, and deliver end-to-end CRO capabilities. Cube Psytech’s competitive advantages and sources of differentiation include (but are not limited to):

  • Innovative R&D & Proprietary Technologies
  • Regulatory Compliance & Licenses
  • World-Class Scientific & Executive Teams
  • Comprehensive CRO Capabilities
  • Strategic Partnerships & Collaborations
  • Focus on Sustainable & Natural Products

For questions or more information, contact: investors@cubepsytech.com

Investor Information